Agilyx's H1 2023 report noted progress, but macro uncertainty and lower customer production activity...
Redeye updates on GiG following its Q2-results which came in stronger than expected driven by strong...
Redeye comments on yesterday’s news that the rights to Mesdopetam have been returned to IRLAB.
Q2 numbers reflect transformation process... ...with e.
OrderYOYO published today, August 22, its half year report of 2023 and are showing continued progres...
Windon Energy Group meddelade den 21 augusti år 2023 att bolaget tecknat sitt första avtal om försäl...
Redeye comments on Scandinavian ChemoTech's strategy update.
Redeye comments on the new study showing that ColdZyme reduces viral load by more than 99% when appl...
PK data for NEX-20 confirms slow-release of lenalidomide Results in line with preclinical studies Na...
Redeye endorses today’s news that the first healthy volunteers have been dosed in the second part of...
Omsättningen ökar drivet av sportsegmentet Björn Borgs omsättning i Q2 uppgick till 166 mkr (162 mkr...
Redeye endorses the positive results from Nanexa’s clinical phase I trial with NEX-20, a long-acting...
Redeye concludes that Kontigo Care’s Q2’23 report was slightly softer than expected.
Agilyx published its H1 2023 report this morning, with progress in place and a back-end loaded 2023 ...
Redeye provides a preview ahead of MGI’s Q2’2023 report, due on 31st of August.
Redeye provides an update following Nitro Games Q2 2023 report, which showed somewhat softer figures...
Redeye provides a research update on the back of Xavi Solutions’ Q2 2023 report.
Redeye provides an update on Thunderful Group following its Q2 2023 report, which showed weaker prof...
IRLAB gets back mesdopetam rights from Ipsen Plans to move mesdopetam into Ph 3 confirmed Conf call ...
Lyckegård publicerade den 21 augusti 2023 bolagets delårsrapport för det andra kvartalet år 2023 och...
